FDA Approves First-In-Class Targeted Therapy for Metastatic Pancreatic Cancer

26 Aug 2026 · 14:40 UTC

Observed price moves

RVMD+3.77%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.